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Abstract
Background: The RE-DUAL PCI trial demonstrated that in patients with nonvalvular
atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual ther-
apy with dabigatran and a P2Y12 inhibitor, either clopidogrel or ticagrelor, reduced
the risk of bleeding without an increased risk of thromboembolic events as compared
to triple therapy with warfarin in addition to a P2Y12 inhibitor and aspirin. What
remains unclear is whether this effect is consistent between males and females
undergoing PCI.
Hypothesis: The reduction in risk of bleeding without increased risk of thromboem-
bolic events with dual therapy with dabigatran and a P2Y12 inhibitor in comparison
to triple therapy with warfarin, a P2Y12 inhibitor and aspirin is consistent in females
and males.
Methods: The primary safety endpoint was the first International Society on Throm-
bosis and Hemostasis (ISTH) major bleeding event (MBE) or clinically relevant non-
major bleeding event (CRNMBE). The efficacy endpoint was the composite of death,
thromboembolic event (stroke, myocardial infarction, and systemic embolism) or
unplanned revascularization. Cox proportional hazard regression analyses were
applied to calculate corresponding hazard ratios and interaction p values for each
endpoint.
Results: A total of 655 women and 2070 men were enrolled. The risk of major or
CRNM bleeding was lower with both dabigatran 110 mg dual therapy and dabigatran
150 mg dual therapy compared with warfarin triple therapy in female and male
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patients (for 110 mg: females: HR 0.69, 95% CI 0.47–1.01, males: HR 0.46, 95% CI
0.37–0.59, interaction p value: 0.084 and for 150 mg: females HR 0.74, 95% CI
0.48–1.16, males HR 0.71, 95% CI 0.56–0.90, interaction p value: 0.83). There was
also no detectable difference in the composite efficacy endpoint of death, thrombo-
embolic events or unplanned revascularization between dabigatran dual therapy and
warfarin triple therapy, with no statistically significant interaction between sex and
treatment (interaction p values: 0.73 and 0.72, respectively).
Conclusions: Consistent with the overall study results, the risk of bleeding was lower
with dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple ther-
apy, and risk of thromboembolic events was comparable with warfarin triple therapy
independent of the patient's sex.
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1 | INTRODUCTION
Sex differences in treatments and outcomes are increasingly recog-
nized in medicine, particularly in cardiovascular medicine. Previous
studies suggest females are underrepresented in clinical trials, with
less female-specific data in terms of drug safety and efficacy.1,2
Women with heart disease including atrial fibrillation are older and
have more co-morbidities, and the potential benefit–risk of new ther-
apies for both adverse cardiovascular events as well as bleeding may
differ.3–10 For patients with atrial fibrillation who undergo percutane-
ous coronary intervention (PCI), this balance is particularly important
– with high risk of thrombotic events and bleeding.
The Randomized Evaluation of Dual Antithrombotic Therapy with
Dabigatran versus Triple Therapy with Warfarin in Patients with Non-
valvular Atrial Fibrillation Undergoing Percutaneous Coronary Inter-
vention (RE-DUAL PCI) trial assessed the safety and efficacy of
dabigatran dual therapy at doses of 110 or 150 mg with a P2Y12
inhibitor (either clopidogrel or ticagrelor) versus warfarin plus aspirin
(ASA) and a P2Y12 inhibitor (either clopidogrel or ticagrelor) in patients
with AF undergoing PCI. We assessed whether outcomes seen in
RE-DUAL PCI are generalizable and applicable to females. We then
compared these results to those of four other trials comparing triple
therapy to dual therapy so as to gain a broader perspective and allow
tailoring of therapy to the specific needs of females.
2 | METHODS
2.1 | Trial design and treatment
The design and the results of the RE-DUAL PCI trial (NCT02164864)
have been reported previously.11,12 Briefly, 2725 patients were ran-
domly assigned to receive dual therapy with dabigatran 110 or
150 mg twice daily plus either clopidogrel or ticagrelor, or to receive
triple therapy with warfarin (adjusted to achieve an international
normalized ratio of 2.0–3.0) plus ASA (≤100 mg daily) and either
clopidogrel or ticagrelor. Outside the United States, patients aged
≥80 years (≥70 years in Japan) were randomized only to the 110 mg
dabigatran dose versus warfarin in order to be consistent with the
labeling of dabigatran in elderly patients in non-US countries. The
study was approved by each center's institutional review board and all
patients provided written informed consent.
All patients received clopidogrel (75 mg daily) or ticagrelor (90 mg
twice daily) for ≥12 months after randomization. In the warfarin triple
therapy group, ASA was discontinued after 1 month in patients
implanted with a bare-metal stent (BMS) and after 3 months in
patients with a drug-eluting stent (DES).
2.2 | Patients
Inclusion criteria, as detailed previously, included males and females
aged ≥18 years with non-valvular AF who underwent PCI with a BMS
or DES within the previous 120 h.11,12 The indication for PCI included
both acute coronary syndrome (ACS) or stable coronary artery dis-
ease. Exclusion criteria included patients with bioprosthetic or
mechanical heart valves, severe renal insufficiency (creatinine clear-
ance <30 ml/min at screening, calculated by the Cockcroft-Gault
equation) or other major coexisting conditions.
2.3 | Assessments
The primary endpoint was the time to a first International Society on
Thrombosis and Hemostasis (ISTH) major bleeding events (MBEs) or
clinically relevant non-major bleeding events (CRNMBEs) during
follow-up (mean 14 months). Additionally, we evaluated the rates of
Thrombolysis in Myocardial Infarction (TIMI) major and minor bleeds
and intracranial hemorrhage (ICH) events. The time to the composite
endpoint of death, thromboembolic events (myocardial infarction,
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stroke or systemic embolism), or unplanned revascularization (first
event) was evaluated, and the individual rates of MI, definite stent
thrombosis, stroke, CV death and all-cause death, respectively.
2.4 | Statistical analysis
For the comparison of dabigatran 110 mg dual therapy versus warfa-
rin triple therapy within the two subgroup categories (male vs female),
stratified Cox proportional hazard regression models were applied,
which included age as a stratifying factor (non-elderly vs elderly ages:
<70 vs ≥70 years in Japan and <80 vs ≥80 years elsewhere) and treat-
ment arm. For the dabigatran 150 mg dual therapy versus warfarin tri-
ple therapy comparison, corresponding unstratified Cox proportional
hazard regression models were applied (excluding patients aged
≥80 years [≥70 years in Japan] outside the United States).
Corresponding hazard ratios (HRs) and two-sided 95% Wald confi-
dence intervals (CIs) for HRs were calculated for each subgroup cate-
gory. Exploratory treatment by subgroup interaction p values resulting
from Cox proportional hazard regression models were provided.
Bleeding and thromboembolic outcomes were assessed according to
treatment group and by sex (female vs male).
2.5 | Comparison across trials
The assessments in the primary endpoint of bleeding and the main ische-
mic/thromboembolic endpoint by sex as seen in RE-DUAL PCI was com-
pared with those same endpoints in four other trials: WOEST, PIONEER
AF-PCI, ENTRUST-AF PCI, and AUGUSTUS.13–16 Individual trial defini-
tions of bleeding and ischemia were used. Hazard ratios, 95% CIs, and
interaction p values delineated by sex were presented in the trial results
in all but WOEST and ENTRUST-AF PCI for which the data was provided
by Prof. Jurrien ten Berg and Prof. Pascal Vranckx, respectively.
3 | RESULTS
3.1 | Patient characteristics
A total of 2725 patients were randomized; 2070 patients were male
(76.0%) and 655 (24.0%) were female. Overall females were older at
time of PCI than males (73.2 ± 7.9 vs 70.0 ± 8.8 years). By definition,
the mean CHA2DS2-VASc scores were higher in females than in males
(4.5 versus 3.3). The HAS-BLED scores were similar in females than in
males (2.8 vs 2.7) (Table 1). Of the 327 patients who received
ticagrelor, 74 were female (22.6%) and of the 2363 patients who
received clopidogrel, 577 were female (24.4%).
3.2 | Bleeding events
Looking at the event rates, females tended to have higher rates of
ISTH MBE or CRNMBE compared to males, a finding seen in other CV
trials.4,17,18 Treatment effects of dual therapy with dabigatran dosed
at 110 mg versus warfarin triple therapy were consistent for females
and males for this endpoint (females: HR 0.69, 95% CI 0.47–1.01,
males: HR 0.46, 95% CI 0.37–0.59, interaction p value: 0.08) (Figure 1).
Consistent treatment effects were also seen for the primary endpoint
with dual therapy with dabigatran dosed at 150 mg vs triple therapy
with warfarin in female and male patients (females HR 0.74, 95% CI
0.48–1.16, males HR 0.71, 95% CI 0.56–0.90, interaction p value:
0.83). In the evaluation of the total bleeds, ISTH MBE and CRNMBE,
Thrombolysis in Myocardial Infarction (TIMI) major bleeds, TIMI minor
bleeds, and intracranial hemorrhage (ICH) individually, no statistically
significant interaction between sex and treatment for both 110 mg
and 150 mg of dabigatran dual therapy versus warfarin triple therapy
could be detected (Table 2).
3.3 | Thromboembolic events
No interaction between sex and treatment was observed for dual ther-
apy with dabigatran at either the 110 mg or 150 mg doses vs triple
therapy with warfarin with regard to the composite efficacy endpoint
of death, thromboembolic events or unplanned revascularization (inter-
action p values: 0.73 and 0.72). When MI, stent thrombosis, stroke, CV
death and all cause death were evaluated individually, no statistically
significant interaction between treatment and sex were observed in any
of these outcomes with either the 110 mg or 150 mg doses of
dabigatran dual therapy versus warfarin triple therapy although the
numbers of events for many of these individual endpoints is small which
limits its interpretation. (Table 2).
3.4 | Comparison across trials
There were considerably fewer females than males included in
WOEST, PIONEER AF-PCI, ENTRUST-AF PCI, and AUGUSTUS, with
each trial enrolling 25% females across all trials. Similar to the results
from RE-DUAL PCI, the results from WOEST, PIONEER AF-PCI,
ENTRUST-AF PCI, and AUGUSTUS showed no interaction between
sex and treatment for neither the bleeding endpoint nor the ischemic/
thromboembolic endpoint (Table 3).
4 | DISCUSSION
There is growing recognition of a need to consider sex differences in
both risk-stratification and efficacy of treatments in cardiovascular
disease.3 In addition to their under-representation in large clinical tri-
als, studies have shown that females have a higher likelihood of com-
plications such as bleeding related to coronary revascularization
procedures.19–22 Moreover, females over the age of 75 with AF are at
higher risk of stroke than males, and strokes in females with AF are
more severe, have higher mortality and recovery is less complete than
in males.23–26 Females with coronary artery disease and AF have
higher stroke risk than males, yet are treated less aggressively for
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primary and secondary stroke prevention than males.27 It is therefore
crucial to delineate differences in treatment response between males
and females with AF treated with anticoagulation undergoing PCI.
This subgroup analysis of the RE-DUAL PCI trial studied potential
interactions between sex and treatment with dual therapy with
dabigatran and P2Y12 inhibition versus triple therapy with warfarin,
P2Y12 inhibition, and aspirin specifically in the setting of patients with
AF undergoing PCI. Consistent with the overall study results, we
found no statistically significant interaction between sex and treat-
ment, suggesting that both female and male patients with AF under-
going PCI benefit from a strategy of dual antithrombotic therapy with
dabigatran in preference to triple therapy with warfarin. To our
knowledge, this is the first dedicated subgroup analysis in the context
of AF and PCI to delineate the sex-interaction in antithrombotic treat-
ment response. To gather a broader perspective, we tabulated the
subgroup information by sex from our study and the four studies
WOEST, PIONEER AF-PCI, ENTRUST-AF PCI, and AUGUSTUS.13–16
(Table 3) In all these trials, a similar finding was seen as in RE-DUAL
PCI: there was no significant interaction between sex and treatment
in the benefit see for a lower bleeding risk, nor any difference in
thromboembolic events.13–16
In the AUGUSTUS trial in particular, the investigators separately
compared the rates of thrombotic events and bleeding between the
oral anticoagulants apixaban and warfarin, and the addition of aspirin
to oral anticoagulation and P2Y12 inhibition. In the endpoint of time
to first ISTH MBE or CRNMBE between apixaban and warfarin, they
found no interaction between sex and treatment in the superiority of
apixaban compared to warfarin. In the efficacy endpoint of time to
death or ischemic events, no difference between apixaban and warfa-
rin was found, which held true of both males and females. AUGUSTUS
also found a significant increase in bleeding without a difference in
the ischemic endpoint for those treated with aspirin versus placebo in
both males and females without a significant interaction between sex
and treatment.16
All these trials all had considerably lower recruitment of females
than males, with numbers comparable to that found in RE-DUAL PCI
(about 25%). However, when considered together, our analysis sug-
gests no difference in safety and efficacy of dabigatran, and other
NOACs as a class, between males and females in their use after PCI
for patients with AF. The results of the overall RE-DUAL PCI trial and
indeed all the trials in this area appear to be generalizable to both
females and males.
F IGURE 1 The risk of bleeding and major ischemic events (death and thromboembolic events) by patient sex. HR and 95% CIs from Cox
proportional hazard regression model stratified by age (elderly vs non-elderly) for dabigatran 110 mg dual therapy versus warfarin triple therapy,
and unstratified for dabigatran 150 mg dual therapy versus warfarin triple therapy. For the comparison with dabigatran 150 mg dual therapy,
elderly patients outside the United States are excluded. CI, confidence interval; CRNMBE, clinically relevant nonmajor bleeding event; DE,
dabigatran etexilate; DTE, death or thromboembolic event; HR, hazard ratio; ISTH, International Society on Thrombosis and Hemostasis; MBE,
major bleeding event
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Total bleed 77 (30.4) 94 (40.7) 0.68 0.50–0.92 189 (26.0) 327 (43.6) 0.50 0.42–0.60 0.10
ISTH MBE 16 (6.3) 20 (8.7) 0.72 0.38–1.40 33 (4.5) 70 (9.3) 0.47 0.31–0.71 0.28
CRNMBE 34 (13.4) 47 (20.3) 0.62 0.40–0.96 81 (11.1) 146 (19.5) 0.52 0.40–0.69 0.53
TIMI Major Bleed 1 (0.4) 8 (3.5) 0.12 0.01–0.92 13 (1.8) 29 (3.9) 0.45 0.23–0.87 0.21
TIMI Minor Bleed 7 (2.8) 9 (3.9) 0.70 0.26–1.87 8 (1.1) 26 (3.5) 0.31 0.14–0.69 0.22







(%) (n = 171)
Warfarin
triple therapy






(%) (n = 592)
Warfarin
triple therapy
(%) (n = 594)
Hazard
ratio 95% CI
Total bleed 58 (33.9) 64 (37.6) 0.84 0.59–1.20 196 (33.1) 252 (42.4) 0.68 0.57–0.82 0.30
ISTH MBE 12 (7.0) 14 (8.2) 0.84 0.39–1.81 31 (5.2) 50 (8.4) 0.59 0.37–0.92 0.44
CRNMBE 28 (16.4) 35 (20.6) 0.75 0.45–1.23 98 (16.6) 113 (19.0) 0.81 0.62–1.06 0.77
TIMI Major Bleed 3 (1.8) 7 (4.1) 0.42 0.11–1.62 13 (2.2) 23 (3.9) 0.54 0.27–1.06 0.75
TIMI Minor Bleed 5 (2.9) 4 (2.4) 1.20 0.32–4.48 7 (1.2) 17 (2.9) 0.40 0.16–0.96 0.16



























All cause death 14 (5.5) 11 (4.9) 1.18 0.54–2.60 41 (5.6) 37 (4.9) 1.11 0.71–1.73 0.90
CV death 8 (3.2) 6 (2.6) 1.23 0.43–3.56 29 (4.0) 25 (3.3) 1.16 0.68–1.97 0.90
MI 12 (4.7) 7 (3.0) 1.60 0.63–4.06 32 (4.4) 22 (2.9) 1.48 0.86–2.55 0.90
Stent thrombosis 5 (2.0) 3 (1.3) 1.60 0.38–6.71 10 (1.4) 5 (0.7) 2.02 0.69–5.92 0.79


























All cause death 7 (4.1) 8 (4.7) 0.86 0.31–2.38 23 (3.9) 27 (4.5) 0.81 0.47–1.42 0.91
CV death 4 (2.3) 5 (2.9) 0.79 0.21–2.96 17 (2.9) 19 (3.2) 0.85 0.44–1.64 0.93
MI 5 (2.9) 6 (3.5) 0.81 0.25–2.65 21 (3.5) 16 (2.7) 1.29 0.67–2.47 0.50
Stent thrombosis 1 (0.6) 3 (1.8) 0.33 0.03–3.16 6 (1.0) 4 (0.7) 1.48 0.42–5.25 0.25
Stroke 2 (1.2) 2 (1.2) 1.00 0.14–7.11 7 (1.2) 6 (1.0) 1.12 0.38–3.34 0.91
Abbreviations: CV, cardiovascular; CRNMBE, clinically relevant non-major bleeding event; ICH, intracranial hemorrhage; ISTH, international society on
thrombosis and hemostasis; NA, one of the categories had an n of 0 in which a hazard ratio is not generated; TIMI: thrombolysis in myocardial infarction.
Note: HR and 95% CIs from Cox proportional hazard regression model stratified by age (elderly vs non- elderly) for dabigatran 110 mg dual therapy versus
warfarin triple therapy, and unstratified for dabigatran 150 mg dual therapy versus warfarin triple therapy. For the comparison with dabigatran 150 mg
dual therapy, elderly patients outside the United States are excluded.
ECCLESTON ET AL. 1007
TABLE 3 Overview of five trials comparing dual versus triple therapy in females versus males
Endpoint of bleeding (trial definition)
N n Relative frequency Hazard ratio (dual vs triple) 95% CI Interaction p value
WOEST Male 448 97 0.22 0.4 0.26–0.62 0.83
Female 115 31 0.27 0.34 0.17–0.72
PIONEER AF-PCI Male 1026 224 0.22 0.63 0.47–0.84 0.45
Female 368 102 0.28 0.51 0.32–0.80
RE-DUAL PCI (dabigatran 110 mg) Male 1478 307 0.21 0.46 0.37–0.59 0.084
Female 484 108 0.22 0.69 0.47–1.01
RE-DUAL PCI (dabigatran 150 mg) Male 1186 272 0.23 0.71 0.56–0.90 0.83
Female 341 78 0.23 0.74 0.48–1.16
ENTRUST-AF PCI Male 1126 224 0.20 0.79 0.594–1.039 0.50
Female 384 80 0.21 0.93 0.598–1.434
AUGUSTUS (apixaban vs warfarin) Male 3228 406 0.13 0.7 0.57–0.85 0.86
Female 1321 167 0.13 0.66 0.48–0.90
AUGUSTUS (aspirin vs placebo) Male 3231 408 0.13 1.98 1.62–2.43 0.38
Female 1325 163 0.12 1.67 1.22–2.30








WOEST Male 448 66 0.15 0.64 0.39–1.05 0.61
Female 115 15 0.13 0.53 0.17–1.35
PIONEER AF-PCI Male 1027 49 0.05 1.16 0.66–2.03 0.65
Female 362 28 0.08 0.877 0.45–1.98
RE-DUAL PCI (dabigatran 110 mg) Male 1478 214 0.14 1.16 0.89–1.52 0.73
Female 484 66 0.14 1.05 0.65–1.70
RE-DUAL PCI (dabigatran 150 mg) Male 1186 148 0.12 0.92 0.66–1.27 0.72
Female 341 40 0.12 0.82 0.43–1.50
ENTRUST-AF PCI Male 1120 71 0.06 1.02 0.641–1.631 0.76
Female 386 24 0.06 1.14 0.520–2.502
AUGUSTUS (apixaban vs warfarin) Male 3277 217 0.07 0.95 0.72–1.23 0.86
Female 1337 100 0.07 0.9 0.61–1.34
AUGUSTUS (aspirin vs placebo) Male 3277 217 0.07 0.9 0.69–1.18 0.80
Female 1337 100 0.07 0.85 0.57–1.26
Note: Definitions of primary bleeding and thrombotic end points as defined in each trial.11,13–16 Data from WOEST and ENTRUST-AF PCI provided by Prof
Jurrien ten Berg and Prof Pascal Vranckx, respectively.
Abbreviations: AF, atrial fibrillation; ASA, aspirin; CI, confidence interval; PCI, percutaneous coronary intervention.
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5 | LIMITATIONS
As in any exploratory subgroup analysis, this analysis is not ade-
quately powered, and no definitive statistical conclusion should be
drawn from its results. In addition, consistent with many large car-
diovascular trials, there is considerable imbalance with fewer females
than males enrolled in the RE-DUAL PCI trial which restricts defini-
tive comparisons between the groups. Therefore, all results should
be regarded as hypothesis-generating rather than definitive evi-
dence. However, this subgroup analysis adds to a growing body of
knowledge exploring differences in sex in response to anti-
thrombotic treatment for cardiovascular disease and will be of inter-
est to practicing cardiologists.
6 | CONCLUSION
This subgroup analysis of the RE-DUAL PCI trial suggests no differ-
ence in benefit on safety and similarity on thromboembolic efficacy
between females and males, supporting the use of dabigatran dual
therapy over warfarin triple therapy in both sexes.
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